Neuroinflammation and Neuroinfection: Genetic Underpinnings to Neuroinflammatory and Neuroinfectious Diseases*

Date: Sunday, September 15, 2024
Time: 3:30 PM to 5:00 PM
Room: Lake Hart
Track: Cross-Cutting Special Interest Group
Level: ANA2024

Description

While there is growing recognition of the genetic underpinnings to many neuroinfectious and neuroinflammatory conditions, the biological mechanisms and clinical presentations require knowledge sharing amongst academic neurologists. Here, we will learn from national and international leaders in the field of genetics as it relates to neuroinfectious and neuroinflammatory conditions to understand when, how and why to consider genetic testing in our patients and recent scientific advances in this rapidly evolving field. Here, we will highlight the latest basic science, translational and clinical research in genetic disorders and neuroinfectious and neuroinflammatory diseases.

Objectives

  • Diagnose and consider a genetic cause of neuroinfectious and neuroinflammatory conditions.

  • Apply genetic testing in the evaluation of patients with presumed and definitive neuroinfectious and neuroinflammatory conditions.

  • Define how to target immune mediated genetic defects which may predispose individuals to these conditions.

  • Neurological Manifestations of Errors of Immunity

    Description

    Inborn Errors of Immunity (IEIs) refer to genetic defects in immune-related genes that control host defense and immune response regulation. Among these patients, neurological disorders often represent a significant cause of morbidity and mortality. However, our understanding of the clinical presentations and underlying mechanisms of IEIs affecting neurons or the central nervous system (CNS) immune compartment remains limited. This presentation aims to introduce a novel platform designed to enhance the investigation of IEIs' role in the nervous system, providing an overview of various neurological manifestations associated with IEI. Additionally, insights from in-depth immunological and genetic investigations will be shared, highlighting their crucial role in diagnosing and treating patients with atypical and refractory neuroinflammatory and neuroinfectious diseases.

  • The White Matter Rounds Experience: An International Network to Accelerate the Diagnosis of Adult Subjects with Atypical White Matter Diseases

    Description

    Adult genetic leukoencephalopathies are rare neurological disorders that present unique diagnostic challenges due to their clinical and radiological overlap with more common white matter diseases, notably multiple sclerosis (MS). In this context, collaborative multidisciplinary networks become critical to shorten the diagnostic odyssey of patients and preventing misdiagnosis. The White Matter Rounds (WM Rounds) network includes physicians and scientists from more than 15 participating sites around the world who gather every month to discuss patients with atypical white matter disorders. The experience of the WM Rounds Network demonstrates the usefulness of collective case discussions to accelerate the diagnostic process and prevent misdiagnosis in patients with rare or atypical white matter diseases. allow Besides allowing neurologists to compare and share information on challenging cases from across the world, networks of this nature provide a basis for multicenter research studies, and serve as model for other rare diseases.

  • Utilization of Cerebrospinal Fluid IgM and RT-PCR Testing for Neuro-invasive West Nile Virus

    Description

    Neuro-invasive West Nile Virus infection is a major cause of neurologic infections in endemic areas. Typically, in immunocompetent patients, diagnosis relies on detection of West Nile-specific IgM antibodies in CSF. In cases where patients are unable to mount an antibody response due to immunosuppression, a combination of WNV-specific IgM and PCT testing may be appropriate. We conducted a comprehensive analysis of testing utilization at two tertiary hospitals in Boston, Massachusetts, examining the medical records of adult patients who underwent West Nile-specific IgM or PCR testing from the CSF between 2016 and 2023. Most patients tested for neuro-invasive West Nile Virus relied solely on PCR for diagnosis, regardless of immune status. Rates of positive testing were low. This departure from guidelines in the majority of cases could potentially result in missed diagnoses and increased healthcare expenditures.